Skip to main content

Health condition · Clinically reviewed

Follicular lymphoma, an indolent B-cell lymphoma with a long-term plan.

Most follicular lymphomas grow slowly. The right first step is often careful watching, not urgent treatment - and when treatment is needed, the options have never been broader.

A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK haemato-oncology clinician before publication.

  • 02

    Sourced from guidance

    Checked against BSH, ESMO, NICE and peer-reviewed haematology sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including obinutuzumab, CAR-T therapy, bispecific antibodies and EZH2 inhibitors.

Key facts

Follicular lymphoma at a glance.

The essentials, in plain English - who gets it, how it behaves, and how it is treated in the UK today.

  • What it is

    The most common indolent B-cell non-Hodgkin lymphoma - roughly one in five NHL diagnoses in the UK.

  • Who it affects

    Median age at diagnosis is around 60 - uncommon under 40 and very rare in children.

  • Molecular hallmark

    t(14;18)(q32;q21) translocation drives BCL2 overexpression and blocks apoptosis in the germinal centre B cell.

  • Grading

    Grades 1, 2 and 3A behave indolently. Grade 3B is aggressive and treated like diffuse large B-cell lymphoma.

  • Course

    Often waxing and waning over years - many patients are watched safely before any treatment starts.

  • Transformation

    Around 2 to 3 per cent per year risk of transformation to a more aggressive lymphoma across the lifetime.

Why this guide matters

A chronic condition with a real toolbox.

Follicular lymphoma often behaves as a long-term condition. Three ideas shape how it is managed and how the rest of this page fits together.

  • Timing matters

    For asymptomatic low burden disease, careful monitoring often beats early treatment. Starting when treatment is genuinely needed matters more than starting quickly.

  • Antibody-based therapy is the backbone

    Rituximab and obinutuzumab, alone or with chemotherapy, are the foundation of modern first-line care - with maintenance for two years after response.

  • Relapse options have transformed

    Lenalidomide plus rituximab, EZH2 inhibitors, PI3K inhibitors, CAR-T therapy and bispecific antibodies are all now part of UK practice.

How the diagnosis is made

From the first swollen node to a clear MDT plan.

The steps a UK haematology team will normally follow, in order - so you know what to expect and why each test is done.

  1. 01

    Assessing

    Full history and examination

    A careful search for lymph nodes, splenomegaly and B symptoms - fever, drenching night sweats and unexplained weight loss.

  2. 02

    Assessing

    Excisional lymph node biopsy

    The preferred sample - a whole node sent to specialist haematopathology. Core biopsy is a second choice when excision is not possible.

  3. 03

    Assessing

    Immunohistochemistry panel

    CD20, CD10, BCL2 and BCL6 positive with CD5 and CD23 negative - Ki-67 helps grade proliferation.

  4. 04

    Confirming

    Molecular confirmation

    t(14;18) BCL2 rearrangement by FISH or PCR supports the diagnosis and can be used later to monitor disease.

  5. 05

    Confirming

    PET-CT staging (Lugano)

    Whole-body FDG PET-CT stages the disease, guides biopsy of any high-uptake site and screens for possible transformation.

  6. 06

    Confirming

    Blood tests and viral screen

    FBC, LDH, beta-2 microglobulin, LFTs and HIV, hepatitis B and C serology - essential before any rituximab-based therapy.

  7. 07

    Planning

    FLIPI risk score and MDT plan

    FLIPI and FLIPI-2 categorise risk. A specialist haemato-oncology MDT then agrees the plan - often at a commissioned lymphoma centre.

Typical timeline: a first suspicious node to an agreed plan usually takes a few weeks.

Symptoms

What follicular lymphoma actually looks like.

Slow, painless lymph node swelling is by far the commonest pattern. Many patients feel entirely well - and some are diagnosed by chance.

  • Painless lymphadenopathy

    Slow-growing, rubbery neck, armpit or groin nodes - classically waxing and waning over months or years.

  • B symptoms

    Fever, drenching night sweats and unexplained weight loss - less common than in aggressive lymphomas but important when present.

  • Fatigue

    A common and often under-recognised feature - can precede any obvious swelling by many months.

  • Splenomegaly

    An enlarged spleen can cause left upper abdominal fullness or early satiety - see our guide to an enlarged spleen for context.

  • Bone marrow involvement

    Sometimes causes anaemia, low platelets or low neutrophils on a routine blood test - occasionally the first clue.

  • Extranodal disease

    Rarely gastrointestinal, testicular, skin or central nervous system involvement - each has its own treatment considerations.

  • Incidental finding

    Many follicular lymphomas are picked up on scans done for another reason - and can be safely observed at first.

  • Red flag - possible transformation

    Rapidly growing nodes, new B symptoms, rising LDH or a hot PET spot may signal transformation to diffuse large B-cell lymphoma.

Treatment

How follicular lymphoma is treated in the UK.

A ladder that starts with careful observation, moves through anti-CD20 antibody therapy with or without chemotherapy, and now extends to CAR-T and bispecific antibodies.

  • Watch and wait

    For asymptomatic low tumour burden disease - large trials show no survival benefit from starting treatment early.

  • Involved-site radiotherapy

    Around 24 Gy for truly localised stage I disease - can produce long remissions and, in selected cases, cure.

  • R-CHOP or R-CVP or R-bendamustine

    Standard first-line chemoimmunotherapy for symptomatic advanced disease - regimen chosen with fitness and comorbidity in mind.

  • Obinutuzumab plus chemotherapy

    An anti-CD20 antibody (Gazyvaro) that improved progression-free survival versus rituximab in the GALLIUM trial - specialist commissioned.

  • Rituximab maintenance

    Two years of maintenance after response - the PRIMA study showed longer time to next treatment.

  • Lenalidomide plus rituximab (R2)

    A chemotherapy-free option in the relapsed setting, supported by the AUGMENT trial - specialist prescribing.

  • CAR-T cell therapy

    Axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) for relapsed or refractory disease - specialist commissioned NHS centres.

  • Bispecific antibodies

    Mosunetuzumab, glofitamab, epcoritamab and odronextamab redirect T cells against CD20 - a growing option in relapsed disease.

Advanced options

Relapsed and refractory disease.

Beyond first-line chemoimmunotherapy, UK haematology teams increasingly use targeted and cellular options. These include the EZH2 inhibitor tazemetostat for EZH2-mutated disease, PI3K inhibitors such as idelalisib, duvelisib, copanlisib and parsaclisib, CAR-T therapy (axicabtagene ciloleucel and tisagenlecleucel), bispecific antibodies (mosunetuzumab, glofitamab, epcoritamab and odronextamab) and, in selected younger fit patients, allogeneic stem cell transplant. Supportive care - vaccinations, IVIG for hypogammaglobulinaemia and PJP prophylaxis - runs alongside disease-directed therapy at every step.

What this guide is based on

The sources behind every claim on this page.

UK and European guidance, plus the pivotal trials that shape modern follicular lymphoma care.

Key references

Guidelines and trials we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haematology team knows your biopsy, imaging and blood tests and can tell you which parts apply to you. Always follow their plan first.

  • British Society for Haematology (BSH). Guidelines for the management of follicular lymphoma.

  • ESMO. Newly diagnosed and relapsed follicular lymphoma - clinical practice guidelines.

  • NICE. Technology appraisals for obinutuzumab, axicabtagene ciloleucel and mosunetuzumab in follicular lymphoma.

  • Lugano Classification. Response criteria and staging for lymphoma.

  • Blood Cancer UK and Lymphoma Action. Patient information on follicular lymphoma.

Red flags

When follicular lymphoma needs urgent attention.

Most day-to-day follicular lymphoma is managed in scheduled clinics. These are the situations that will not wait - and where a same-day call to your team or A&E is right.

  • Rapid nodal growth

    A node that doubles in size over weeks, rather than months, raises the possibility of transformation to a more aggressive lymphoma.

  • New B symptoms

    Fresh fevers, drenching night sweats or unexplained weight loss during watchful waiting should always prompt urgent review.

  • Rising LDH

    A new or rising lactate dehydrogenase - especially with a hot PET spot - is a classic marker of possible transformation.

  • Spinal cord compression

    Back pain with limb weakness, sensory change or bladder or bowel disturbance is an emergency - call 999 or go straight to A&E.

  • Ureteric obstruction

    Bulky retroperitoneal nodes can obstruct one or both ureters - flank pain, reduced urine output or acute kidney injury need urgent assessment.

  • Severe infection while on treatment

    Fever, rigors or unusual breathlessness during or after chemoimmunotherapy - especially with a low neutrophil count - is a haematology emergency.

  • Central nervous system symptoms

    Rare in follicular lymphoma but new confusion, headaches, seizures or focal neurology need urgent imaging.

  • Symptomatic cytopenias

    Marked anaemia, bruising or bleeding may reflect bone marrow involvement or treatment effect and needs prompt blood tests.

  • Late effects of therapy

    Second cancers, cardiac and thyroid effects can follow years of treatment - long-term follow-up matters.

Living with it

A long-term condition, with a supportive team.

Four things that make the biggest difference over the years - the mindset, the follow-up rhythm, vaccinations, and the charities and peers who understand this diagnosis.

A quiet reminder

A new symptom is a reason to call, not to wait.

Rapid growth, new B symptoms or worrying blood tests deserve a phone call to your haematology team - long before your next scheduled appointment.

  1. 01 Mindset

    A long-term condition, not an emergency

    Most people live for many years with follicular lymphoma. Framing it as a chronic condition often helps day to day.

  2. 02 Follow-up

    Regular clinic and blood tests

    Even during watch and wait, a scheduled review picks up change early - and gives you a chance to raise new symptoms.

  3. 03 Vaccines

    Stay on top of vaccinations

    Flu, COVID-19 and pneumococcal vaccines matter more after rituximab or obinutuzumab. Your team will guide the timing.

  4. 04 Support

    Lean on charities and peers

    Lymphoma Action, Blood Cancer UK and Macmillan run helplines, forums and information days worth knowing about.

Frequently asked

Everything we get asked about follicular lymphoma.

Straight answers on watch and wait, FLIPI, transformation and the newest UK options.

  • What is follicular lymphoma?

    Follicular lymphoma is the most common indolent B-cell non-Hodgkin lymphoma. It arises from germinal centre B cells and typically carries the t(14;18) translocation, which drives BCL2 overexpression and blocks the normal death of these cells. It usually behaves as a long-term relapsing and remitting condition rather than an acute illness.

  • Why might my team recommend watch and wait?

    For asymptomatic patients with low tumour burden disease, large trials show that starting treatment straight away does not improve survival compared with careful monitoring. Watch and wait avoids side effects until treatment is genuinely needed. Your team will use criteria such as GELF and clinical judgement to decide when to start.

  • What does the FLIPI score tell me?

    FLIPI and FLIPI-2 are risk scores that combine age, stage, haemoglobin, LDH, nodal areas and beta-2 microglobulin. They group patients into low, intermediate and high-risk categories and help your team predict how the disease is likely to behave. They do not decide treatment on their own but inform the discussion.

  • Is follicular lymphoma curable?

    Truly localised stage I disease can sometimes be put into very long remission - or effectively cured - with involved-site radiotherapy. Most patients have more advanced disease that is treated as a long-term chronic condition, with repeated remissions rather than a single curative treatment. Newer options such as CAR-T therapy are changing that picture in relapsed disease.

  • What does transformation mean?

    Transformation is when follicular lymphoma changes into a more aggressive lymphoma, most often diffuse large B-cell lymphoma. It happens at a rate of roughly 2 to 3 per cent per year across a lifetime. Signs include rapidly growing nodes, new B symptoms and a rising LDH. Treatment then follows aggressive lymphoma protocols.

  • What are the new treatments for relapsed follicular lymphoma?

    Options in the relapsed setting now include lenalidomide plus rituximab (R2), PI3K inhibitors, the EZH2 inhibitor tazemetostat for EZH2-mutated disease, CAR-T therapies such as axicabtagene ciloleucel and tisagenlecleucel, and bispecific antibodies such as mosunetuzumab, glofitamab, epcoritamab and odronextamab. These are delivered at specialist commissioned NHS centres.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.